
    
      This proof-of-concept study is a randomized, parallel design of two different oral doses of
      QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark
      adaptation.

      Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the
      US.
    
  